Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings

References

• Spearing MK. Schizophrenia. A detailed booklet that describes symptoms, causes, and treatments, with information on getting help and coping [scientific information and review were provided by David Shore and John K. Hsiao]. National Institute of Mental Health (NIMH). 1999
   Google Scholar
• Mauskopf JA, David K, Grainger DL, Gibson PJ. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry 1999;60:14–9
   PubMed Web of Science ®Google Scholar
• Guest JF, Cookson RF. Cost of schizophrenia to UK society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999;15:597–610
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Practice guidelines for the treatment of patients with schizophrenia, 2nd ed. American Psychiatric Association; 2004 http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf
   Google Scholar
• Correll CU, Leucht S, Kane JM. Reduced risk of tardive dyskinesia with second-generation antipsychotics: a systematic review of one-year studies. Am J Psychiatry 2004;161(3):414–25
   Google Scholar
• Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics part 1: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33(1):73–85
   Google Scholar
• Revicki, DA. 1999. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 19991;35 (Suppl):S101–9
   Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotic olanzapine, quetiapine, risperidone, and sertindole, compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51–68
   PubMed Web of Science ®Google Scholar
• Sartorius N, Fleischhacker WW, Gjerris A, et al. The usefulness and use of second-generation antipsychotic medications. Curr Opin Psychiatry 2002;15(Suppl 1):S1–S51
   Web of Science ®Google Scholar
• National Institute of Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Institute for Clinical Excellence; 2002 (http://www.nice.org.uk)
   Google Scholar
• Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res 2003;31(3):188–96
   Google Scholar
• Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 1997;4(5):255–71
   PubMed Web of Science ®Google Scholar
• Revicki DA. The new atypical antipsychotics: a review of pharmacoeconomic studies. Expert Opin Pharmacother 2000;1(2):249–60
   PubMedGoogle Scholar
• Revicki DA. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr Opin Investig Drugs 2001;2(1):110–7
   PubMedGoogle Scholar
• Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003; 36(1): 18–26
   Google Scholar
• Awad AG, Vorunganti LN. Quality of life and new antipsychotics in schizophrenia: are patients better off?” Int J Soc Psychiatry 1999;45(4):268–75
   PubMed Web of Science ®Google Scholar
• Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: part II: adverse effects, drug interactions, and costs. Ann Pharmacother 1999;33(2):210–7
   PubMed Web of Science ®Google Scholar
• Stark C, Jones J, Agnew J, Hepburn T. Anti-psychotic drug prescription trends in primary care in Scotland 1994–97. Health Bull (Edinb.) 2000;58(2):96–101
   PubMedGoogle Scholar
• Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P. How much are atypical antipsychotics agents being used, and do they reach the population who need them? A Canadian experience. Clin Ther 2002;24(9):1466–76
   Google Scholar
• Jerrel JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medication. Schizophr Bull 2002;28(4):589–605
   PubMed Web of Science ®Google Scholar
• Daumit GL, Crum RM, Gullar E, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry 2003;60(2):121–8
   PubMed Web of Science ®Google Scholar
• Kozma CM, Mody SH, Sadik MK. A comparative analysis of risperidone and olanzapine dosing patterns in the South Carolina Medicaid program [poster presentation at the Annual Meeting of the American Psychiatric Association] 1999
   Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, Ernst FR. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 200402;3(1):11
   Google Scholar
• Lucey JV, Libretto SE. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis. Ire J Med Sci 2003;172(4):195–201
   PubMed Web of Science ®Google Scholar
• Masand PS, Wang X, Gupta S, Schwartz TL, Virk S, Hameed A. Comparison of risperidone and olanzapine in bipolar and schizoaffective disorder. Prim Care Companion J Clin Psychiatry 2002;4(2):70–3
   PubMedGoogle Scholar
• Taylor DM, Wright T, Libretto SE. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS) [UK Investigator Group]. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003;64(5):589–97
   Google Scholar
• Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J. Cost evaluation of risperidone compared with olanzapine. Psychiatric Services 2003;54(5):742–4
   PubMed Web of Science ®Google Scholar
• Schwartz TL, Saba M, Hardoby W, Virk S, Masand PS. Use of atypical antipsychotics in a Veterans Affairs hospital. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(6):1207–10
   Google Scholar
• Kasper S, Jones M. Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001;16(4):189–96
   Google Scholar
• Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Services 2001;52(5):676–8
   Google Scholar
• Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998;20:1203–17
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Lichtenberg P, Kaplan Z. Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr Res 2000;46:91–6
   Google Scholar
• Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL. Olanzapine versus risperidone in the treatment of schizophrenia. Pharmacoeconomics 2003;21:683–97
   Google Scholar
• Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Managed Care 1998;4(3):345–55
   Google Scholar
• Foster RH, Goa KL. Olanzapine. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999;15(6):611–40
   Google Scholar
• Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Managed Care Interface 2002;15:75–81
   PubMedGoogle Scholar
• Fuller MA, Shermock KM, Secic M, Laich JS, Durkin MB. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Services 2002;53(7):855–60
   Google Scholar
• Johnsrud M, Crismon, Grogg A, Thomson A. Risperidone and olanzapine utilization and expenditures within the Texas Medicaid program [poster]. American Psychiatric Association Annual Meeting, New Orleans, LA; May 2001
   Google Scholar
• Grogg AL, Damiano A, Malkin J, Sadik K. Medicaid costs of schizophrenia patients initiating atypical antipsychotics. APA-IPS 2002
   Google Scholar
• Nightengale BS, et al. Dosing trends and health care costs from a state medicaid perspective: risperidone vs. olanzapine [poster]. APA; May 1999
   Google Scholar
• Edgell WS, Rupnow MF. Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorder and Alzheimer’s disease. Manag Care Interface 2003;16(5):64–7
   PubMedGoogle Scholar
• Medical economics company. Red Book ™ for Windows®. 2001
   Google Scholar
• Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Int Med 1997;127:757–63
   PubMed Web of Science ®Google Scholar
• D’Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265–81
   PubMed Web of Science ®Google Scholar
• Irish W, Neighbors D, Grogg A, et al. Using propensity scores to adjust for treatment selection bias: review of methods plus an extension for use in studies with three or more treatment groups. Poster presentation at the ISPOR Fourth Annual European Congress 2001
   Google Scholar
• Hosmer DW, Lemeshow S. Applied logistic regression. New York (NY): John Wiley and Sons, 1989
   Google Scholar
• Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28 (Suppl 1):9–26
   PubMed Web of Science ®Google Scholar